Tumor DNA mapping may unlock personalized cancer therapies

NCT ID NCT02290522

Recruiting now Knowledge-focused Sponsor: Ulrik Lassen Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profiling. The goal is to see if this genomic screening approach can improve how long patients live without their disease progressing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor biopsy for molecular characterization
What this could lead to: If successful, this approach could help doctors select more effective, personalized treatments for people with advanced solid tumors who have run out of standard options.
What could go wrong: This is an early, exploratory study. It may not prove that genomic screening improves outcomes, and biopsies carry risks such as bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC

Contacts and locations

Locations

Rigshospitalet
RECRUITING

Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.